Danapha Pharmaceutical JSC (HSTC:DAN) EBIT: ₫ Mil (TTM As of . 20)


HSTC:DAN Danapha Pharmaceutical JSC HSTC:DAN
30 GF Score
Price ₫30,300.00
! 1 Warning Sign
View Full Analysis

What is Danapha Pharmaceutical JSC EBIT?

Danapha Pharmaceutical JSC HSTC:DAN 30 EBIT is ₫ Mil as of . 20. GuruFocus rates HSTC:DAN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Danapha Pharmaceutical JSC's earnings before interest and taxes (EBIT) for the six months ended in . 20 was ₫0.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Danapha Pharmaceutical JSC  (HSTC:DAN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Danapha Pharmaceutical JSC's annualized ROC % for the quarter that ended in . 20 is calculated as:

ROC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Note: The Operating Income data used here is one times the annual (. 20) data.

2. Joel Greenblatt's definition of Return on Capital:

Danapha Pharmaceutical JSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

ROC (Joel Greenblatt) %(Q: . 20 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: . 20  Q: . 20
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=/( ( ( + max(, 0)) + ( + max(, 0)) )/ )
=/( ( + )/ )
=/
= %

where Working Capital is:

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (. 20) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Danapha Pharmaceutical JSC's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: . 20 )
=/634421.400
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Danapha Pharmaceutical JSC EBIT Related Terms

Danapha Pharmaceutical JSC EBIT Historical Data

* Premium members only.

The historical data trend for Danapha Pharmaceutical JSC's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Danapha Pharmaceutical JSC EBIT Chart

Danapha Pharmaceutical JSC Annual Data
Trend
EBIT

Danapha Pharmaceutical JSC Semi-Annual Data
EBIT

HSTC:DAN vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Danapha Pharmaceutical JSC's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Danapha Pharmaceutical JSC EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Danapha Pharmaceutical JSC's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Danapha Pharmaceutical JSC's EV-to-EBIT falls into.


HSTC:DAN
30GF Score
Danapha Pharmaceutical JSC HSTC:DAN
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Danapha Pharmaceutical JSC EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in . 20 was ₫ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₫ Mil mean?
Danapha Pharmaceutical JSC (HSTC:DAN) has a EBIT of ₫ Mil as of . 20. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Danapha Pharmaceutical JSC.
Is Danapha Pharmaceutical JSC's EBIT too high?
Danapha Pharmaceutical JSC's current EBIT is ₫ Mil. Overall, Danapha Pharmaceutical JSC has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Danapha Pharmaceutical JSC's EBIT compare to ZTS and UTHR?
Danapha Pharmaceutical JSC's EBIT of ₫ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Danapha Pharmaceutical JSC. Danapha Pharmaceutical JSC's current EBIT is ₫ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danapha Pharmaceutical JSC stock overvalued right now?
Danapha Pharmaceutical JSC (HSTC:DAN) has a current EBIT of ₫ Mil. The current EBIT is ₫ Mil. Danapha Pharmaceutical JSC's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Danapha Pharmaceutical JSC (HSTC:DAN), the current EBIT is ₫ Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Danapha Pharmaceutical JSC Business Description

Address 253 Dung Si Thanh Khe, Da Nang, VNM
Danapha Pharmaceutical JSC is a manufacturer of herbal medicine and specific drugs such as central nervous system, neurotonics, anti-diabetics, cardiovascular drug, gastrointestinal and heaptic biliary system with forms such as tablets, capsules, injection, sirup, balm and medicated oil.
30GF Score

Get the complete analysis for HSTC:DAN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫30,300.00
Price